Source: Eye Future ；Editor: SophiaReprint Requirements: Can be reprinted 24 hours after the first publication, source must be credited.
Recently, an ophthalmology innovation therapy biotechnology company ——Arctic Vison Hong Kong Biotech Limited (Abbreviation: Arctic Vison)Announced that its subsidiaryNew Generation iTEAR Muqing® Self-Induced Lacrimal Secretion DeviceOfficial Launch,Used to stimulate the external nasal nerve, increase tear production, and improve dry eye symptoms in adult patients.。The product, asThe First in ChinaProduct for Improving Dry Eye Symptoms by Stimulating the External Nasal Nerve, alsoThe First in ChinaNatural Tear Secretion Enhancement Therapy for Dry Eye, providing a new treatment option for patients with dry eye.In June 2021, Arctic Vison and U.S.-based Olympic Ophthalmics, a company specializing in ophthalmic neurotherapies, announcedSign an Exclusive License Agreement，Arctic Vison will be responsible for the latter's developed medical device for treating dry eye syndrome.iTEAR®100 Development and Commercial Sales in Greater China, South Korea, and ASEAN Countries。The product isThe First to Gain FDA Approval(2020) A device that promotes natural tear secretion through non-invasive stimulation of the external nasal nerve.External Nasal Nerve Stimulation for Dry Eye Treatment has been approved as a medical device in both China and the United States.Upgraded Version iTEAR Muqing® Natural Tear StimulatorEven more byArctic Vison InvitesRenowned in the international design communityCo-designed by design company Frog Design, enhancing the user experience from multiple dimensions such as sensory touch, grip angle, and portability.# Research and Development BackgroundIn recent years, with the popularity of electronic products, changes in people's living environment and lifestyle, as well as the extension of average life expectancy,The prevalence of dry eye continues to rise.By 2021, the number of dry eye patients in China approached 300 million, andIncreasing by 10% annually。In ophthalmic clinics, the proportion of dry eye patients can be as high as 30%.Dry eye has become one of the important issues affecting the eye health of the Chinese population.Data shows,Asia has one of the highest global rates of dry eye incidence, with China's incidence rate approximately 21%-30%.。Dry eye is increasingly recognized as a serious public health issue and has become one of the most common reasons for people seeking eye care.One of the main core factors in the pathogenesis of dry eye is tear film instability.Rebuilding Tear Film Homeostasis is the Main Treatment Goal for Dry EyeTherefore, the existing dry eye treatment methods are mainly divided intoTargeted supplementation or repair of certain components of the tear filmandRegulation of Natural Tear SecretionFor instance, artificial tears that emphasize hydration, physical treatments targeting the lipid layer such as meibomian gland warm compresses, massage, and intense pulsed light therapy. However, the rich composition of natural tears is difficult to replace, coupled with the diverse causes of dry eye disease,Many patients are not satisfied with the effectiveness of existing treatment methods.。The physiological secretion of tears is mainly controlled by neural pathways., which includes the ocular surface sensory nerve endings that perceive external stimuli and the effector organs responsible for secreting tear components, such as the lacrimal gland, meibomian glands, and conjunctival goblet cells.The nasolacrimal reflex constitutes another important neural pathway., that isThe sensory nerves of the nasal region transmit stimulation signals via the anterior ethmoidal nerve to the effector, thereby controlling tear secretion.。Therefore, artificial stimulation of related nerves, especiallyThe upstream and downstream pathways of the nasolacrimal reflex can effectively promote tear secretion., has become a potential treatment for dry eye.Studies have shown that nasal neural pathways play an important role in maintaining tear film homeostasis, participating in the regulation of basal and reflex tearing.Nasal neurostimulation was included as a recommended treatment in the second edition of the International Dry Eye Workshop Guidelines in 2017.。In view of the above background, iTEAR Muqing® adopts a novel mechanism to stimulate natural tear secretion through external nasal nerve stimulation. It is easy to operate, non-invasive, portable, and safe with mild adverse reactions. It can also simultaneously promote the secretion of natural tears containing water, lipids, and mucin, comprehensively improving the symptoms and signs of dry eye. Additionally, the use of iTEAR Muqing® can effectively reduce the dependence on artificial tears, bringing good news to a wide range of dry eye patients.# iTEAR Mùqìn® Natural Tear Stimulator
iTEAR Muqing® UseNon-invasive technology，Stimulating the external nasal nerve through unique vibration frequencies，Promote the secretion of your own tears, All-natural, Zero Preservatives, Zero Medicinal Properties.Usage: Place the probe of the handheld device on the skin between the nasal cartilage and the nasal bone for use.Frequency of Use: Twice daily, stimulating each side for 30 seconds per session.Mechanism of Action: Vibrating stimulation of the anterior ethmoidal nerve's external nasal branch to stimulate natural tear secretion.- Takes effect immediately, with a 3.7-fold increase in natural tear production after application.；
- Basic tear secretion levels significantly increased by 57% over 30 days, promote the recovery of the ability to secrete tears naturally;
- Slow down the evaporation rate of tears, effectively improving tear film stability (TBUT +34%) and significantly alleviating symptoms and signs of dry eye.
iTEAR Muqin®Introduction Video of Autologous Tear Secretion StimulatorThe emergence of iTEAR Muqing® Natural Tear Stimulator marks a new era in dry eye treatment through external nasal nerve stimulation.# Clinical Trial Results
For iTEAR Muqin®,Eye, Ear, Nose and Throat Hospital of Fudan UniversityConductedPhase I Clinical Trial。
The principal investigator of the clinical trial is Professor Gong Lan, Chief Physician at the Eye, Ear, Nose, and Throat Hospital affiliated with Fudan University, Head of the Ocular Surface Disease Specialist Group, Doctor of Medicine, and Doctoral Supervisor.
Professor Gong Lan Shared "A New Option for Dry Eye Patients —— Nasal Nerve Stimulation Promotes Physiological Tear Secretion" at the 2024 China Corneal Disease Forum & The 23rd National Academic Conference on Corneal and Ocular Surface Diseases of China and The 16th Annual Meeting of National Corneal Refractive Surgery of ChinaClinical TrialProgress shows:iTEAR Muqin®Promote Tear SecretionSignificant Effect, the baseline tear secretion, immediate tear secretion, and tear meniscus height all increased significantly after stimulation;
Rapid Onset，Significant increase in tear secretion levels after stimulation;
Basic tear secretion levelSignificant Improvement, which can help restore tear film stability in patients with dry eye,Significant Improvement in Dry Eye Symptoms and Signs。
The trial demonstrated the efficacy of iTEAR.®Good SafetyNo serious adverse events (AE) occurred during the experiment, and no subjects paused or withdrew from the study due to AE.After 14 days, only 6 patients experienced mild nasal itching, and 1 patient developed sneezing symptoms.
# Products Based on Electrical Stimulation——TrueTearTrueTear Handheld Intranasal Tear Neurostimulator(abbreviated as TrueTear, Allergan, Ireland)Approved for marketing by the US FDA in 2017, asThe First Launched Neurostimulation Lacrimal Instrument, bringing an innovative treatment method for dry eye patients.The device isHandheld Intranasal Neurostimulationin the way, throughRelease microcurrent to stimulate the trigeminal nerve endings in the nasal mucosa, thereby stimulating tear secretion.This uniquely designed stimulation methodDirectly Acting on Nerve Impulses, with a significant effect on promoting tear secretion. One of the advantages of TrueTear is itsUnique Electrical Stimulation Design, able toDirectly Activate Nerve Impulses, thereby promoting tear secretion in a short period of time.However, TrueTear also has some disadvantages.：The deviceMay causeNasal pain, discomfort, burning sensation, nosebleeds, and nasal congestionetc.Adverse Reactions,ItsDisposable Nasal Electrode ConsumablesBrought byHigh CostAlso limits its feasibility in long-term applications.Overall, TrueTear, as the first marketed neurostimulation-induced tear device, has provided new insights into the field of dry eye treatment and validated the feasibility of this approach.In addition, its drawbacks and the situation of production termination also provided references for later designs.。
Arctic Vison is a China-based company focused onOphthalmology Innovation TherapyBiotechnology company with capabilities spanning from the early discovery stage to the commercialization stage.A Portfolio of Breakthrough Ophthalmic Therapies。Arctic Vison was founded with the support of professional investment firms in the life sciences sector and is managed by a team of industry elites with extensive experience in global ophthalmic product research, development, and commercialization.The company’s vision is to address unmet clinical needs in the field of ophthalmic diseases by providing innovative therapies in China, across Asia, and globally, benefiting a wide range of patients with eye conditions.# Global Leading Ophthalmic Device and Consumables CompanyCarl Zeiss AG｜Alcon| J&J Vision | Bausch + LombBaushe & Lomb | EssilorEssilor | TopconTopcon | Nidek Nidek | CooperC Groupompanies
# Chinese Ophthalmic Devices and Consumables Companies
# China Ophthalmology Medical Service Company
# Overseas Ophthalmology Startups
AEYE Health | Samsara Vision | AcuSurgical | Balance Ophthalmics | CorneaGen | ThermOcular AI
